CE 155
Alternative Names: CE-155; CE155-WNP-mRNALatest Information Update: 04 Mar 2022
At a glance
- Originator Cello Therapeutics
- Class Antineoplastics; Drug conjugates; RNA
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Feb 2022 Cello Therapeutics has patent protection for membrane encapsulate nanoparticles in Taiwan, China, Macao, Japan, Europe (Cello Therapeutics pipeline, February 2022)
- 17 Feb 2022 Cello Therapeutics has patents pending for membrane encapsulate nanoparticles in Hong Kong, China, USA, Europe, Canada and worldwide (Cello Therapeutics pipeline, February 2022)
- 17 Feb 2022 Preclinical trials in Cancer in USA (unspecified route) (Cello Therapeutics pipeline, February 2022)